Pembrolizumab in endometrial cancer: Where we stand now (Review)-Reference-Cited by-同舟云学术

Pembrolizumab in endometrial cancer: Where we stand now (Review)

Published:2021-10-08 Issue:6 Volume:22 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Aravantinou‑Fatorou Aikaterini¹,Andrikopoulou Angeliki²,Liontos Michael²,Fiste Oraianthi²,Georgakopoulou Vasiliki¹,Dimopoulos Meletios-Athanasios²,Gavriatopoulou Maria²,Zagouri Flora²

Affiliation:

1. First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens 11527, Greece

2. Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway;International Immunopharmacology;2024-06

2. Temporal Trends in Treatment and Outcomes of Endometrial Carcinoma in the United States, 2005–2020;Cancers;2024-03-26

3. Predicting Mismatch Repair Deficiency Status in Endometrial Cancer through Multi-Resolution Ensemble Learning in Digital Pathology;Journal of Imaging Informatics in Medicine;2024-02-20

4. Developing predictive biomarkers for endometrial cancer immunotherapy with mass cytometry (CyTOF);Revealing Unchartered Biology with Single Intact Cells;2024

5. Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents;The Journal of Clinical Pharmacology;2023-11